drugset
drugset / Trial / NCT03500627

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of OP-101 After Intravenous Administration in Healthy Volunteers

NCT03500627 ↗

Phase 1 Completed 8 enrolled Orpheris, Inc.
Non-randomizedSequentialOpen-labelTreatment

Summary

A clinical study to measure the effect of OP-101 after being administered intravenously in healthy volunteers.

Timeline

Start
2018-03-30
Primary completion
2018-07-20
Completion
2018-07-20

Drugs

EvaluationDrugModalityDoseRoute
Subject ACETYLCYSTEINE ZIDRIMER Small molecule 20 mg/kg Intravenous
Subject ACETYLCYSTEINE ZIDRIMER Small molecule 40 mg/kg Intravenous
Subject ACETYLCYSTEINE ZIDRIMER Small molecule 80 mg/kg Intravenous

Indications

No indication recorded.